Overview

This trial is active, not recruiting.

Condition coronary artery disease
Treatment sirolimus target eluting bioresorbable vascular scaffold
Sponsor Shanghai MicroPort Medical (Group) Co., Ltd.
Start date January 2016
End date May 2016
Trial size 45 participants
Trial identifier NCT02659254, MicroPort_Firesorb_FIM

Summary

This study is a small scale pilot trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) in Patients with Coronary Artery Disease for the first time. The goal is to access the preliminary safety and efficacy of Firesorb implantation in the human body, and to provide evidence for subsequent large-scale, multi-center, randomized controlled clinical trials. Then provide the basis for the formal application of the product in China.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb)in patients with coronary artery lesions.
sirolimus target eluting bioresorbable vascular scaffold Firesorb
Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold

Primary Outcomes

Measure
Device-oriented composite endpoints (Target Lesion Failure)
time frame: 1 month after index procedure

Secondary Outcomes

Measure
Target Lesion Failure
time frame: 6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Patient-oriented clinical composite endpoint (PoCE)
time frame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Device Success
time frame: From the start of index procedure to end of index procedure
Procedural Success
time frame: At time of procedure up to 7 days in hospital
Scaffold Thrombosis/Stent Thrombosis (per ARC definition)
time frame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
In-device, in-segment, proximal and distal minimum lumen diameter (MLD)
time frame: 6 months,1 year,2 years and 3 years after index procedure
In-device, in-segment, proximal and distal % diameter stenosis (DS)
time frame: 6 months,1 year,2 years and 3 years after index procedure
In-device, in-segment, proximal and distal angiographic binary restenosis (ABR)
time frame: 6 months,1 year,2 years and 3 years after index procedure
In-device, in-segment,proximal and distal late lumen loss (LLL)
time frame: 6 months,1 year,2 years and 3 years after index procedur
Vasomotion
time frame: 6 months,1 year,2 years and 3 years after index procedure

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. 18-75 years of age, males or non-pregnant females; 2. With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction; 3. Total number of target lesion is 1; 4. Target lesion length ≤ 25mm (Visual); target lesion diameter between 3.0mm to 3.75mm; 5. Visual assessment of target lesion diameter stenosis ≥ 70%,TIMI blood flow≥1; 6. Each target lesion may be covered by a single stent; 7. Patients with indications for coronary artery bypass graft surgery; 8. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. Exclusion Criteria: 1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal; 2. Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months; 3. Severe congestive heart failure (NYHA class III and above) ,left ventricular ejection fraction or <40% (ultrasound or left ventricular angiography); 4. Preoperative renal function serum creatinine >2.0mg/DL; receiving hemodialysis; 5. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; 6. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; 7. The patient's life expectancy is less than 12 months; 8. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; 9. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; 10. Heart transplantation patients; 11. The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia; 12. Cancer need chemotherapy; 13. Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy; 14. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc; 15. Within six months for elective surgery requires stopping aspirin, Clopidogrel patients; 16. Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis); 17. Peripheral vascular disease, 6F catheter is not available.

Additional Information

Official title The Feasibility and Safety Evaluation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) in Patients With Coronary Artery Disease for the First Time: a Prospective, Single Arm Clinical Trial.(FUTURE-I)
Principal investigator Runlin Gao, MD
Description This study is a prospective, single-center clinical trial. The investigator design to recruit 45 subjects. After implanting the Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) successfully, all the subjects will be randomly assigned to queue 1 (n=30) and queue 2 (n=15). The clinical follow-up will be performed in all subjects at 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after scaffold implantation. Angiographic,IVUS and OCT follow-up will be performed at 6 months and 2 years after scaffold implantation in queue 1; angiographic,IVUS and OCT follow-up will be performed at 1 year and 3 years after scaffold implantation in queue 2. The primary endpoint of the study is target lesion failure (TLF) at 30 days after scaffold implantation, the secondary endpoints are series of imaging outcomes, for evaluation of feasibility and preliminary safety and efficacy of the product.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Shanghai MicroPort Medical (Group) Co., Ltd..